SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Condition(s):Small Cell Lung CancerLast Updated:July 14, 2023Recruiting
Include Studies Not Open or Pending
Condition(s):Small Cell Lung CancerLast Updated:July 14, 2023Recruiting
Condition(s):Metastatic Biliary Tract CancerLast Updated:February 28, 2024Recruiting
Condition(s):Colorectal Cancer; Peritoneal MetastasesLast Updated:August 22, 2023Recruiting
Condition(s):Malignant Tumor; DiarrheaLast Updated:September 13, 2023Recruiting
Condition(s):Small Cell Lung Cancer RecurrentLast Updated:February 14, 2024Not yet recruiting
Condition(s):Rectal Cancer Stage IIILast Updated:December 8, 2021Recruiting
Condition(s):Rectal CancerLast Updated:March 8, 2024Recruiting
Condition(s):Extensive-stage Small-cell Lung CancerLast Updated:March 27, 2024Not yet recruiting
Condition(s):Gastric CancerLast Updated:December 9, 2022Not yet recruiting
Condition(s):Fruquintinib; Irinotecan; Capecitabine; Gastrointestinal TumoursLast Updated:December 13, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.